Pathomorphological analysis of nonalcohoholic and alcoholic steathohepatitis adverse consequences

Authors

  • V. A. Tumansky Zaporizhzhia State Medical University, Ukraine
  • S. V. Fen’ Zaporizhzhia State Medical University, Ukraine
  • L. M. Tumanskaya Zaporizhzhia State Medical University, Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2017.4.59-74

Keywords:

non-alcoholic and alcoholic steatohepatitis, liver cirrhosis, hepatocellular cancer

Abstract

Background. Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are widespread in all countries, they are complicated by cirrhosis and liver cancer, which cause death to 4% of the world's population.The early diagnosis of these diseases in trepanobioptates of the liver and the prediction of their course is of particular importance. Objective. pathomorphological analysis of activation and complications of NASH and ASH manifestations in biopsy section material. Methods. 185 histopathological and histochemical and immunohistochemical studies of NASH, ASH, cirrhosis and liver cancer were performed in 185 liver trepanobioptates and in the sectional material of 451 patients. Results. The following pathomorphological signs of activation of NASH and ASH are revealed: transient growth of hepatocyte steatosis, increased inflammation-cell infiltration of hepatic lobules, an increase in the number of hepatocytes with Mallory-Denk bodies and neutrophilic-cellular satellitosis, an increase in the incidence of necroptosis, apoptosis and balonization (balloon lysis) of hepatocytes, and infrequent signs: the increase in immunocellular killing, autophagy in hepatocytes and the deposition of iron in the liver. The indicator of severity and duration of NASH and ASH is perisinusoidal pericellular and portal-Z3perisinusoidal hepatic fibrosis, progressing from a mild F1 degree, through an average F2 degree to severe F3 fibrosis. Conclusion. Adverse complications of NASH and ASH is micronodular cirrhosis of the perisinusoidal pericellular or portal-Z3perisinusoidal type, as well as rarely developing hepatocellular liver cancer.

References

  1. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely mid-dle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31. doi: 10.1053/j.gastro.2010.09.038.
  2. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and nonalcoholic steatohepatitis distinct conditions? Aliment. Pharmacol. Ther. 2012;36(9):815–23. doi:10.1111/apt.12046
  3. Brown GT, Kleiner DE. Histopathology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Metabolism. 2016;65(8):1080–6. doi: 10.1016/j.metabol.2015.11.008.
  4. Adams LA, Ratziu V. Non-alcoholic fatty liver - perhaps not so benig. J. Нepatol. 2015;62(5):1002–4. doi: 10.1016/j.jhep.2015.02.005.
  5. Kleiner DE, Makhlouf HR. Histology of NAFLD and NASH in Adults and Children. Clin. Liver. Dis. 2016;20(2):293–312. doi: 10.1016/j.cld.2015.10.011
  6. Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct enti-ties? Curr. Hepatol. Rep. 2014;13(2):151–8. doi: 10.1007/s11901-014-0227-5
  7. Stockwell T, Zhao J, Greenfield T, Li J, Livingston M, Meng Y. Estimating under- and over-reporting of drinking in national surveys of alcohol consumption: identification of consistent biases across four English-speaking countries. Addiction. 2016;111(7):1203-13. doi: 10.1111/add.13373.
  8. Tu HP, Tung YC, Tsai WC, Lin GT, Ko YC, Lee SS. Alcohol related diseases and alcohol dependence syndrome is associated with increased gout risk: a nationwide populationbased cohort study. Joint Bone Spine. 2017;84(2):189-96. doi: 10.1016/j.jbspin.2016.02.024.
  9. Lowe JM, McDonell MG, Leickly E, Angelo FA, Vilardaga R, McPherson S, Srebnik D, Roll J, Ries RK. Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients. Alcohol Clin. Exp. Res. 2015;39(5):905-10. doi: 10.1111/acer.12699.
  10. Sumida Y, Nakajima A, Itoh Y. Limita-tions of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gas-troenterol. 2014;20(2):475–85. doi: 10.3748/wjg.
  11. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–32. doi: 10.1002/hep.23594.
  12. Karagozian R, Derdak Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63(5):607–17. doi: 10.1016/j.metabol.2014.01.011.
  13. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease / European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). J. Hepatol. 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004.
  14. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 2014;20(42): 15539–48. doi: 10.3748/wjg.v20.i42.15539.
  15. Stepanov YuM. Hepatic steatosis and stea-tohepatitis is the inevitability of mixed genesis. Gas-trоenterology. 2014;4(54):136-42. Russian.
  16. Kleiner DE, Brunt EM, Van Natta M, Beh-ling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A. Design and validation of a histological scoring system for nonal-coholic fatty liver disease. Hepatology. 2005;41(6):1313–21. doi:10.1002/hep.20701.
  17. Brunt EM, Kleiner DE, Wilson LA., Belt P, Neuschwander-Tetri BA. NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic di-agnosis in NAFLD: distinct clinicopathologic mean-ings. Hepatology. 2011;53(3):810-20. doi: 10.1002/hep.24127.
  18. Hjelkrem M, Stauch C, Shaw J, Harrison S.A. Validation of the non-alcoholic fatty liver dis-ease activity score. Aliment. Pharmacol. Ther. 2011;34(2):214–8. doi: 10.1111/j.1365-2036.2011.04695.x.
  19. Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study. APMIS. 2017;125(11):962-73. doi: 10.1111/apm.12742.
  20. Ferrell L. Pitfalls in the Diagnosis of Medi-cal Liver Disease with two Concurrent Etiologies. Current Issues In Anatomic Pathology. 2017 [el.res. www.ucsfcme.com/2017/MAP17001A/.../13_Ferrell_Liver. pdf]
  21. Rasband WS. (1997–2016) Image. J. Be-thesda, Maryland. Retrived from: http://imagej.nih.gov/ij/
  22. Tumanskyi VO, Fen’ SV. inventors. Za-porizhia state medical university. [A method for de-termining the degree of steatosis in the liver biopsy] Ukraine patent UA 112148. 2016. Int. CI. G01N21/00, А61В1/00. Ukrainian.
  23. Bedossa P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibi-tion of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatol-ogy. 2014;60(2):565–75. doi: 10.1002/hep.27173.
  24. Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, Berloco PB, Cantafora A, Wauthier E, Furth ME, Inverardi L, Dominguez-Bendala J, Ricordi C, Gerber D, Gaudio E, Alvaro D, Reid L. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology. 2011;54(6):2159–72. doi: 10.1002/hep.24590.
  25. Carpino G, Renzi A, Onori P, Gaudio E. Role of Hepatic Progenitor Cells in Nonalcoholic Fatty Liver Disease Development: Cellular Cross-Talks and Molecular Networks. Int. J. Mol. Sci. 2013;14(10):20112-30. doi:10.3390/ijms141020112.
  26. Heymann F, Tacke F. Immunology in the liver — from homeostasis to disease. Nat. Rev. Gas-troenterol. Hepatol. 2016;13(2):88–110. doi:10.1038/nrgastro.2015.200
  27. Tumansky VA, Shishkin MA, Shebeko YuA. Immunocellular Killing: Morphogenesis and сonsequences for рatients with сhronic viral hepati-tis. Pathologia. 2008;5(3):110-2. Russian.
  28. Hung TM, Yuan RH, Huang WP, Chen YH, Lin YC, Lin CW, Lai HS, Lee PH. Increased Autophagy Markers Are Associated with Ductular Reaction during the Development of Cirrhosis. Am. J. Pathology. 2015;185(9):2454–67. doi: 10.1016/j.ajpath.2015.05.010.
  29. Tumanskiy VA, Fen’ SV. Deposition fea-tures of heterovalent iron (Fe2 + and Fe3 +) in the liver in alcoholic and nonalcoholic steatohepatitis. Pathologia. 2015;3(35):41–48. doi: 10.14739/2310-1237.2015.3.55589. Russian.
  30. Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, Neubauer S, Morovat R, Wang LM, Pasricha SR, Fargion S, Col-lier J, Barnes E, Dracesmith H, Valenti L, Pavides M. Hepatic iron is the major determinant of serum ferritin in NAFLD patients. Liver Int. 2018;38(1):164–73. doi.org/10.1111/liv.13513.
  31. Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int. 2016;36(11):1688–95. doi: 10.1111/liv.13144.
  32. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431.
  33. Zhao L, Westerhoff M, Pai RK, Choi WT, Gao ZH, Hart J. Centrilobular ductular reaction cor-relates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis. Modern Pathology advance online publication. 2017; doi:10.1038/modpathol.2017.115
  34. Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism. 2016;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010.
  35. Corey KE, Gawrieh S, deLemos AS, Zheng H, Scanga AE, Haglund JW, Sanchez J, Danford CJ, Comerford M, Bossi K, Munir S, Chalasani N, Wattacheril J. Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J. Hepatol. 2017;9(7):385-90. doi: 10.4254/wjh.v9.i7.385.
  36. Ascha MS, Hanouneh IA, Lopez R, Tami-mi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–8. doi: 10.1002/hep.23527.
  37. White DL, Kanwal F, El–Serag HB. Asso-ciation Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Sys-tematic Review. Clin. Gastroenterology Hepatholo-gy. 2012;10(12):1342–59. doi: 10.1016/j.cgh.2012.10.001.
  38. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S. HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepa-tology. 2016;63(3):827-38. doi: 10.1002/hep.28368.
  39. Perumpail RB, Wong RJ, Ahmed A, Harri-son SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig. Dis. Sci. 2015;60(10):3142-8. doi: 10.1007/s10620-015-3821-7.
  40. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Associ-ation of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–30. doi: 10.1002/hep.28123.
  41. Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J. Gastroenterol. 2017;23(36):6571-92. doi: 10.3748/wjg.v23.i36.6571.
  42. Tilg H, Moschen AR. Mechanisms behind the link between obesity and gastrointestinal can-cers. Best Pract Res. Clin. Gastroenterol. 2014;28(4):599–610. doi: 10.1016/j.bpg.2014.07.006.

Downloads

Published

2017-12-22

How to Cite

Tumansky, V. A., Fen’, S. V., & Tumanskaya, L. M. (2017). Pathomorphological analysis of nonalcohoholic and alcoholic steathohepatitis adverse consequences. Морфологія / Morphologia / Morfologìâ, 11(4), 59–74. https://doi.org/10.26641/1997-9665.2017.4.59-74

Issue

Vol. 11 No. 4 (2017)

Section

Статті

License

Copyright (c) 2017 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.